MedPath

Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide

Phase 2
Completed
Conditions
Prostate Cancer Metastatic
Interventions
Procedure: 11C or 18F-Choline PET/CT
Procedure: Whole body MRI
Procedure: Bone scan
Registration Number
NCT02815033
Lead Sponsor
The European Uro-Oncology Group
Brief Summary

The aim of the study is to assess the clinical utility of 11C or 18F-Choline Positron Emission Tomography (PET)/Computed Tomography (CT) scan, Whole Body Magnetic Resonance Imaging (MRI) versus conventional bone scan and prostate-specific antigen (PSA) measurements in response prediction to treatment with Enzalutamide in Hormono-Sensitive Metastatic Prostate Cancer patients.

The study will assess how these 2 imaging modalities perform compared to traditional serial PSA measurements and bone scan in assessing metastatic tumour load, progressive disease and response to treatment with Enzalutamide.

In addition measurements of serially collected circulating tumour cell (CTC) samples, cell-free tumour DNA and RNA will be performed in order to evaluate their predictive value in terms of response measurement.

Detailed Description

Metastatic prostate cancer patients eligible for 1st line hormonal treatment will undergo treatment with Enzalutamide (XTANDI). Subjects will receive 1dd 160 mg Enzalutamide orally continuously until progressive disease occurs. All subjects will undergo Choline (11C or 18F)-PET/CT scans at baseline, 2 weeks, 2 and 6, 9 and 12 months after starting androgen receptor (AR)-directed treatment. All subjects will undergo Whole Body MRI at baseline, 6, 9 and 12 months. Bone scans will be performed at baseline, 3 months, 6 and 12 months. PSA will be measured at baseline and every 4 weeks thereafter until at 12 months. CTC counts and characteristics will be measured at baseline and during Enzalutamide treatment.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
66
Inclusion Criteria
  • Male aged 18 years or older;
  • Histologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features;
  • Three consecutive rises of PSA, 1 week apart, resulting in two 50% increases over the nadir, with PSA of at least > 2 ng/mL but preferably >20 ng/mL;
  • Progressive disease defined by rising PSA levels plus by evidence of progressive and measurable soft tissue or bone disease by 11C or 18F-Choline PET/CT, Whole Body MRI or both;
  • No prior treatment with cytotoxic chemotherapy;
  • Eastern Cooperative Oncology Group (ECOG) score 0-2;
  • A life expectancy of at least 12 months;
  • Written informed consent;
Exclusion Criteria
  • Treatment with androgen deprivation therapy with a gonadotropin-releasing hormone analogue, luteinizing hormone-releasing hormone antagonist, or bilateral orchiectomy within 6 months of enrolment (Day1 visit);
  • Treatment with anti-androgens such as bicalutamide, nilutamide or flutamide within 6 weeks of enrolment (Day 1 visit);
  • Treatment with 5-α reductase inhibitors (finasteride, dutasteride), estrogens, cyproterone acetate within 4 weeks of enrolment (Day 1 visit);
  • Severe concurrent disease, infection, or co-morbidity that, in the judgment of the Investigator, would make the patient inappropriate for enrolment;
  • Known or suspected brain metastasis or active leptomeningeal disease;
  • History of another malignancy within the previous 5 years other than curatively treated non melanomatous skin cancer;
  • Total bilirubin, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 2.5 times the upper limit of normal at the Screening visit;
  • Creatinine > 177 µmol/L (2 mg/dL) at the Screening visit;
  • Hemoglobin <6 mmol/L, White blood cells < 4.0 x 10^9/L, Platelets < 100 x 10^9/L;
  • History of seizure or any condition that may predispose to seizure. Also, history of loss of consciousness or transient ischemic attack within 12 months of enrolment (Day 1 visit);
  • Contra-indication for MRI (e.g. pacemaker).

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Single arm11C or 18F-Choline PET/CTExperimental: Single arm Subjects will receive 1 dd 160 mg Enzalutamide orally continuously until progressive disease occurs. Serial PSA measurements, PET/CT scans, Whole Body MRI, bone scans will be performed to assess metastatic tumour load, progressive disease and response to treatment.
Single armWhole body MRIExperimental: Single arm Subjects will receive 1 dd 160 mg Enzalutamide orally continuously until progressive disease occurs. Serial PSA measurements, PET/CT scans, Whole Body MRI, bone scans will be performed to assess metastatic tumour load, progressive disease and response to treatment.
Single armBone scanExperimental: Single arm Subjects will receive 1 dd 160 mg Enzalutamide orally continuously until progressive disease occurs. Serial PSA measurements, PET/CT scans, Whole Body MRI, bone scans will be performed to assess metastatic tumour load, progressive disease and response to treatment.
Single armEnzalutamideExperimental: Single arm Subjects will receive 1 dd 160 mg Enzalutamide orally continuously until progressive disease occurs. Serial PSA measurements, PET/CT scans, Whole Body MRI, bone scans will be performed to assess metastatic tumour load, progressive disease and response to treatment.
Primary Outcome Measures
NameTimeMethod
Progression-Free Survival (PFS) at 6 and 12 months.6 and 12 months

Radiological progression is defined by any of the following criteria:

* Soft tissue lesions: Progressive disease on Choline (11C or 18F) PET/CT or Whole Body MRI by RECIST 1.1. Bone or bone marrow lesions: Progressive disease on PET/CT or MRI as evidenced by new lesions or an increase in size of 25% of the sum of target lesions.

* Conversion of the Choline (11C or 18F) PET signal of the metastases at 2 weeks, 2 or 6 months compared to baseline PET which by comparing it to PFS at 6 and 12 months may be an indicator or drug response. Radiological PFS at 6 and 12 months will be compared to a) PET signal conversion and to b) PSA measurements, and changes in number of lesions on the bone scan (conventional work up).

Secondary Outcome Measures
NameTimeMethod
Radiologically confirmed spinal cord compression or pathological fracture due to malignant progression6 and 12 months

Assessment of spinal cord compression or pathological fracture

Biochemical response defined as prostate-specific antigen (PSA) nadir12 months

Assessment of nadir PSA

PSA progression. PSA kinetics measured by PSA doubling time (regular PSA measurements)12 months

PSA doubling time

Progression of bone lesions detected with bone scan according to Prostate Cancer Working Group 2 (PCWG2) criteria6 and 12 months

Bone lesions progression

Occurrence of Symptomatic Skeletal Events (SSE) evaluated by combination of clinical and radiological assessments12 months

SSE is defined as external beam radiation therapy to relieve skeletal pain, occurrence of a new symptomatic pathologic bone fracture, spinal cord compression, tumour-related orthopedic surgical intervention or change of anti-neoplastic therapy to treat bone pain

Circulating tumour cell (CTC) measurements and comparison with radiological PFS at 6 and 12 months6 and 12 months

Assessment of CTC

Percent change from baseline in serum concentration of circulating testosterone (T)12 months

Changes in testosterone from baseline

Percent change from baseline in serum concentration of dihydrotestosterone (DHT)12 months

Changes in dihydrotestosterone from baseline

Percent change from baseline in serum concentration of sex hormone binding globulin (SHBG)12 months

Changes in sex hormone binding globulin

Percent change from baseline in serum concentration of androstenedione (A)12 months

Changes in androstenedione from baseline

Number of participants with changes in biomarkers of bone turnover correlated to PSA12 months

Changes in biomarkers of bone turnover correlated to PSA

Number of participants with adverse events (AEs) and serious adverse events (SAEs) leading to treatment discontinuation6 and 12 months

Assessment of AE and SAEs

Time to symptomatic progression (including death due to prostate cancer)12 months

Time to progression

Time to first radiological or symptomatic progression6 and 12 months

Time to first radiological or symptomatic progression

Time to initiation of salvage systemic therapy, including chemotherapy, or palliative radiation12 months

Time to chemotherapy or palliative radiation

Quality of life measured by the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire6 and 12 months

Quality of Life measurement using questionnaires

Quality of life measured by the EuroQol 5-Dimension QoL Instrument (EQ-5D)6 and 12 months

Quality of life measurement using questionnaire

Changes in Sexual Function (IIEF)6 and 12 months

Changes in Sexual Function from baseline

Changes in Karnofsky score6 and 12 months

Changes in Karnofsky score from baseline

Changes in visual analogue scale (VAS) for tumour-related pain6 and 12 months

Changes in pain from baseline

Changes in bone mineral density (BMD) as measured by Dual-energy X-ray absorptiometry (DXA) scan6 and 12 months

Changes in bone mineral density from baseline

Trial Locations

Locations (1)

Leiden University Medical Center

🇳🇱

Leiden, Netherlands

© Copyright 2025. All Rights Reserved by MedPath